Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Metabolic Complications and Kidney Transplantation: Focus on Glycaemia and Dyslipidaemia

Author(s): Panagiotis Anagnostis*, Stavroula Α. Paschou, Eleftherios Spartalis, Gerardo Sarno, Paride De Rosa and Giovanna Muscogiuri

Volume 18, Issue 3, 2020

Page: [273 - 281] Pages: 9

DOI: 10.2174/1570161117666190619143005

Price: $65

Abstract

Post-transplant diabetes mellitus (PTDM) and dyslipidaemia are the most common metabolic complications in kidney transplant recipients (KTR). They are associated with a higher risk of lower graft function and survival, as well as an increased risk of cardiovascular disease (CVD). The aim of this review is to provide current data on the epidemiology, pathophysiology and optimal management of these two principal metabolic complications in KTR. Several risk factors in this metabolic milieu are either already present or emerge after renal transplantation, such as those due to immunosuppressive therapy. However, the exact pathogenic mechanisms have not been fully elucidated. Awareness of these disorders is crucial to estimate CVD risk in KTR and optimize screening and therapeutic strategies. These include lifestyle (preferably according to the Mediterranean pattern) and immunosuppressive regimen modification, as well as the best available anti-diabetic (insulin or oral hypoglycaemic agents) and hypolipidaemic (e.g. statins) regimen according to an individual’s metabolic profile and medical history.

Keywords: Kidney transplant, post-transplant diabetes mellitus, dyslipidaemia, cardiovascular risk, immunosuppressive therapy, diabetes.

« Previous Next »
Graphical Abstract

[1]
Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69(3): 588-95.
[http://dx.doi.org/10.1038/sj.ki.5000116] [PMID: 16395250]
[2]
Bee YM, Tan HC, Tay TL, Kee TY, Goh SY, Kek PC. Incidence and risk factors for development of new-onset diabetes after kidney transplantation. Ann Acad Med Singapore 2011; 40(4): 160-7.
[PMID: 21678001]
[3]
Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62(4): 1440-6.
[http://dx.doi.org/10.1111/j.1523-1755.2002.kid582.x] [PMID: 12234317]
[4]
Lindholm A, Albrechtsen D, Frödin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60(5): 451-7.
[http://dx.doi.org/10.1097/00007890-199509000-00008] [PMID: 7676492]
[5]
Pannu HS, Singh D, Sandhu JS. Lipid profile before and after renal transplantation--a longitudinal study. Ren Fail 2003; 25(3): 411-7.
[http://dx.doi.org/10.1081/JDI-120021153] [PMID: 12803504]
[6]
Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011; 91(3): 334-41.
[http://dx.doi.org/10.1097/TP.0b013e318203c25f] [PMID: 21242885]
[7]
Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant 2014; 14(9): 1992-2000.
[http://dx.doi.org/10.1111/ajt.12850] [PMID: 25307034]
[8]
Chakkera HA, Weil EJ, Castro J, et al. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol 2009; 4(4): 853-9.
[http://dx.doi.org/10.2215/CJN.05471008] [PMID: 19339426]
[9]
Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23(4): 739-49.
[http://dx.doi.org/10.1681/ASN.2011080835] [PMID: 22343119]
[10]
Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3(2): 178-85.
[http://dx.doi.org/10.1034/j.1600-6143.2003.00010.x] [PMID: 12603213]
[11]
Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3(5): 590-8.
[http://dx.doi.org/10.1034/j.1600-6143.2003.00082.x] [PMID: 12752315]
[12]
Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007; 83(8): 1027-34.
[http://dx.doi.org/10.1097/01.tp.0000259617.21741.95] [PMID: 17452891]
[13]
Dienemann T, Fujii N, Li Y, et al. Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study. Transpl Int 2016; 29(9): 1017-28.
[http://dx.doi.org/10.1111/tri.12807] [PMID: 27284760]
[14]
Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2011; 8(1): 34-42.
[http://dx.doi.org/10.1038/nrneph.2011.174] [PMID: 22083141]
[15]
Sheu A, Depczynski B, O’Sullivan AJ, Luxton G, Mangos G. The effect of different glycaemic states on renal transplant outcomes. J Diabetes Res 2016; 2016 8735782
[http://dx.doi.org/10.1155/2016/8735782] [PMID: 28053992]
[16]
American Diabetes Association. Standards of Medical Care in Diabetes - 2018. Diabetes Care 2018; 41(Suppl. 1): 1-150.
[17]
Hagen M, Hjelmesaeth J, Jenssen T, Morkrid L, Hartmann A. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 2003; 18(10): 2154-9.
[http://dx.doi.org/10.1093/ndt/gfg338] [PMID: 13679495]
[18]
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1): 140-9.
[http://dx.doi.org/10.2337/dc14-2441] [PMID: 25538310]
[19]
Pimentel AL, Cavagnolli G, Camargo JL. Diagnostic accuracy of glycated hemoglobin for post-transplantation diabetes mellitus after kidney transplantation: systematic review and meta-analysis. Nephrol Dial Transplant 2017; 32(3): 565-72.
[http://dx.doi.org/10.1093/ndt/gfw437] [PMID: 28088775]
[20]
Conte C, Secchi A. Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention. Acta Diabetol 2018; 55(8): 763-79.
[http://dx.doi.org/10.1007/s00592-018-1137-8] [PMID: 29619563]
[21]
Starzl TE. Experience in renal transplantation. In: . W.B. Saunders Company: Philadelphia 1964.
[22]
Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983; 6(1): 23-5.
[http://dx.doi.org/10.2337/diacare.6.1.23] [PMID: 6341013]
[23]
Hill CM, Douglas JF, Rajkumar KV, McEvoy J, McGeown MG. Glycosuria and hyperglycaemia after kidney transplantation. Lancet 1974; 2(7879): 490-2.
[http://dx.doi.org/10.1016/S0140-6736(74)92016-9] [PMID: 4136757]
[24]
Baron PW, Infante S, Peters R, et al. Post-transplant diabetes mellitus after kidney transplant in Hispanics and Caucasians treated with tacrolimus-based immunosuppression. Ann Transplant 2017; 22: 309-14.
[http://dx.doi.org/10.12659/AOT.903079] [PMID: 28533501]
[25]
Cron DC, Noon KA, Cote DR, et al. Using analytic morphomics to describe body composition associated with post-kidney transplantation diabetes mellitus. Clin Transplant 2017; 31(9)
[http://dx.doi.org/10.1111/ctr.13040] [PMID: 28640481]
[26]
Cullen TJ, McCarthy MP, Lasarev MR, Barry JM, Stadler DD. Body mass index and the development of new-onset diabetes mellitus or the worsening of pre-existing diabetes mellitus in adult kidney transplant patients. J Ren Nutr 2014; 24(2): 116-22.
[http://dx.doi.org/10.1053/j.jrn.2013.11.002] [PMID: 24411665]
[27]
David-Neto E, Lemos FC, Fadel LM, et al. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007; 84(1): 50-5.
[http://dx.doi.org/10.1097/01.tp.0000267647.03550.22] [PMID: 17627237]
[28]
Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007; 30(3): 609-15.
[http://dx.doi.org/10.2337/dc06-1277] [PMID: 17327329]
[29]
Porrini E, Moreno JM, Osuna A, et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. Transplantation 2008; 85(8): 1133-8.
[http://dx.doi.org/10.1097/TP.0b013e31816b16bd] [PMID: 18431233]
[30]
Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59(2): 732-7.
[http://dx.doi.org/10.1046/j.1523-1755.2001.059002732.x] [PMID: 11168956]
[31]
Shin JI, Palta M, Djamali A, Astor BC. Higher pretransplantation hemoglobin A1c is associated with greater risk of post-transplant diabetes mellitus. Kidney Int Rep 2017; 2(6): 1076-87.
[http://dx.doi.org/10.1016/j.ekir.2017.06.006] [PMID: 29270516]
[32]
de Mattos AM, Olyaei AJ, Prather JC, Golconda MS, Barry JM, Norman DJ. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 2005; 67(2): 714-20.
[http://dx.doi.org/10.1111/j.1523-1755.2005.67132.x] [PMID: 15673321]
[33]
Hamer RA, Chow CL, Ong AC, McKane WS. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83(1): 36-40.
[http://dx.doi.org/10.1097/01.tp.0000248759.37146.3d] [PMID: 17220788]
[34]
Benson KA, Maxwell AP, McKnight AJ. A huge review and meta-analyses of genetic associations in new onset diabetes after kidney transplantation. PLoS One 2016; 11(1) e0147323
[http://dx.doi.org/10.1371/journal.pone.0147323] [PMID: 26789123]
[35]
Lv C, Chen M, Xu M, et al. Influencing factors of new-onset diabetes after a renal transplant and their effects on complications and survival rate. PLoS One 2014; 9(6) e99406
[http://dx.doi.org/10.1371/journal.pone.0099406] [PMID: 24911157]
[36]
Sharif A, Cohney S. Post-transplantation diabetes-state of the art. Lancet Diabetes Endocrinol 2016; 4(4): 337-49.
[http://dx.doi.org/10.1016/S2213-8587(15)00387-3] [PMID: 26632096]
[37]
Le Fur A, Fournier MC, Gillaizeau F, et al. Vitamin D deficiency is an independent risk factor for PTDM after kidney transplantation. Transpl Int 2016; 29(2): 207-15.
[http://dx.doi.org/10.1111/tri.12697] [PMID: 26426441]
[38]
Sarno G, Nappi R, Altieri B, et al. Current evidence on vitamin D deficiency and kidney transplant: What’s new? Rev Endocr Metab Disord 2017; 18(3): 323-34.
[http://dx.doi.org/10.1007/s11154-017-9418-z] [PMID: 28281103]
[39]
Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 2014; 30(2): 96-102.
[http://dx.doi.org/10.1002/dmrr.2486] [PMID: 24123849]
[40]
Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006; 81(6): 845-52.
[http://dx.doi.org/10.1097/01.tp.0000203894.53714.27] [PMID: 16570006]
[41]
Ekberg H, Bernasconi C, Nöldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25(6): 2004-10.
[http://dx.doi.org/10.1093/ndt/gfp778] [PMID: 20106825]
[42]
Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62(7): 900-5.
[http://dx.doi.org/10.1097/00007890-199610150-00005] [PMID: 8878381]
[43]
Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7(6): 1506-14.
[http://dx.doi.org/10.1111/j.1600-6143.2007.01749.x] [PMID: 17359512]
[44]
Chakkera HA, Kudva Y, Kaplan B. Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus. Clin Pharmacol Ther 2017; 101(1): 114-20.
[http://dx.doi.org/10.1002/cpt.546] [PMID: 27804122]
[45]
Verges B. mTOR and cardiovascular diseases: diabetes mellitus. Transplantation 2018; 102(2S Suppl 1): S47-9.
[http://dx.doi.org/10.1097/TP.0000000000001722] [PMID: 28263222]
[46]
Ekstrand AV, Eriksson JG, Grönhagen-Riska C, Ahonen PJ, Groop LC. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. Transplantation 1992; 53(3): 563-9.
[http://dx.doi.org/10.1097/00007890-199203000-00014] [PMID: 1549847]
[47]
Hecking M, Kainz A, Werzowa J, et al. Glucose metabolism after renal transplantation. Diabetes Care 2013; 36(9): 2763-71.
[http://dx.doi.org/10.2337/dc12-2441] [PMID: 23656979]
[48]
Nam JH, Mun JI, Kim SI, et al. beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001; 71(10): 1417-23.
[http://dx.doi.org/10.1097/00007890-200105270-00011] [PMID: 11391229]
[49]
Ramirez SC, Maaske J, Kim Y, et al. The association between glycemic control and clinical outcomes after kidney transplantation. Endocr Pract 2014; 20(9): 894-900.
[http://dx.doi.org/10.4158/EP13463.OR] [PMID: 24641922]
[50]
Hermayer KL, Egidi MF, Finch NJ, et al. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metab 2012; 97(12): 4399-406.
[http://dx.doi.org/10.1210/jc.2012-1979] [PMID: 23074234]
[51]
Klaassen G, Zelle DM, Navis GJ, et al. Lifestyle intervention to improve quality of life and prevent weight gain after renal transplantation: Design of the Active Care after Transplantation (ACT) randomized controlled trial. BMC Nephrol 2017; 18(1): 296.
[http://dx.doi.org/10.1186/s12882-017-0709-0] [PMID: 28915863]
[52]
Pedrollo EF, Nicoletto BB, Carpes LS, et al. Effect of an intensive nutrition intervention of a high protein and low glycemic-index diet on weight of kidney transplant recipients: study protocol for a randomized clinical trial. Trials 2017; 18(1): 413.
[http://dx.doi.org/10.1186/s13063-017-2158-2] [PMID: 28874181]
[53]
Wilcox J, Waite C, Tomlinson L, et al. Comparing glycaemic benefits of Active Versus passive lifestyle Intervention in kidney Allograft Recipients (CAVIAR): study protocol for a randomised controlled trial. Trials 2016; 17: 417.
[http://dx.doi.org/10.1186/s13063-016-1543-6] [PMID: 27550305]
[54]
Paschou SA, Leslie RD. Personalizing guidelines for diabetes management: twilight or dawn of the expert? BMC Med 2013; 11: 161.
[http://dx.doi.org/10.1186/1741-7015-11-161] [PMID: 23841986]
[55]
Upadhyay J, Polyzos SA, Perakakis N, et al. Pharmacotherapy of type 2 diabetes: An update. Metabolism 2018; 78: 13-42.
[http://dx.doi.org/10.1016/j.metabol.2017.08.010] [PMID: 28920861]
[56]
Lo C, Jun M, Badve SV, et al. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Cochrane Database Syst Rev 2017; 2 CD009966
[http://dx.doi.org/10.1002/14651858.CD009966.pub2] [PMID: 28238223]
[57]
European Medicines Agency. Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function 2016. Available from. https://www.ema.europa.eu/en/news/use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function
[58]
Vanhove T, Remijsen Q, Kuypers D, Gillard P. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transplant Rev (Orlando) 2017; 31(2): 69-77.
[http://dx.doi.org/10.1016/j.trre.2016.09.001] [PMID: 27665059]
[59]
Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 2005; 80(10): 1402-5.
[http://dx.doi.org/10.1097/01.tp.0000181165.19788.95] [PMID: 16340782]
[60]
Paschou SA, Dede AD, Anagnostis PG, Vryonidou A, Morganstein D, Goulis DG. Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab 2017; 102(10): 3621-34.
[http://dx.doi.org/10.1210/jc.2017-00042] [PMID: 28938433]
[61]
Andersen ES, Deacon CF, Holst JJ. Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes Metab 2018; 20(1): 34-41.
[http://dx.doi.org/10.1111/dom.13018] [PMID: 28544214]
[62]
Sanyal D, Gupta S, Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. Indian J Endocrinol Metab 2013; 17(Suppl. 1): S203-5.
[http://dx.doi.org/10.4103/2230-8210.119572] [PMID: 24251159]
[63]
Strøm Halden TA, Åsberg A, Vik K, Hartmann A, Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant 2014; 29(4): 926-33.
[http://dx.doi.org/10.1093/ndt/gft536] [PMID: 24452849]
[64]
Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. Am J Transplant 2014; 14(1): 115-23.
[http://dx.doi.org/10.1111/ajt.12518] [PMID: 24279801]
[65]
Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care 2013; 36(10): e171-2.
[http://dx.doi.org/10.2337/dc13-1066] [PMID: 24065848]
[66]
Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 2016; 12(12): 711-2.
[http://dx.doi.org/10.1038/nrneph.2016.159] [PMID: 27847389]
[67]
Gonyea JE, Anderson CF. Weight change and serum lipoproteins in recipients of renal allografts. Mayo Clin Proc 1992; 67(7): 653-7.
[http://dx.doi.org/10.1016/S0025-6196(12)60720-4] [PMID: 1434899]
[68]
Dimény EM. Cardiovascular disease after renal transplantation. Kidney Int Suppl 2002; 80: 78-84.
[http://dx.doi.org/10.1046/j.1523-1755.61.s80.14.x] [PMID: 11982818]
[69]
Tse KC, Lam MF, Yip PS, Li FK, Lai KN, Chan TM. A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant 2004; 18(3): 274-80.
[http://dx.doi.org/10.1111/j.1399-0012.2004.00160.x] [PMID: 15142048]
[70]
Badiou S, Garrigue V, Dupuy AM, Chong G, Cristol JP, Mourad G. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? Transplant Proc 2006; 38(7): 2314-6.
[http://dx.doi.org/10.1016/j.transproceed.2006.07.003] [PMID: 16980076]
[71]
Ettinger WH, Bender WL, Goldberg AP, Hazzard WR. Lipoprotein lipid abnormalities in healthy renal transplant recipients: persistence of low HDL2 cholesterol. Nephron 1987; 47(1): 17-21.
[http://dx.doi.org/10.1159/000184450] [PMID: 3306427]
[72]
Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9(5): 531-2.
[http://dx.doi.org/10.2174/157016111796642698] [PMID: 21595629]
[73]
Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9(5): 533-71.
[http://dx.doi.org/10.2174/157016111796642661] [PMID: 21595628]
[74]
Anagnostis P, Karras S, Lambrinoudaki I, Stevenson JC, Goulis DG. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. Int J Clin Pract 2016; 70(12): 967-77.
[http://dx.doi.org/10.1111/ijcp.12903] [PMID: 28032426]
[75]
Kerschdorfer L, König P, Neyer U, et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 1999; 144(2): 381-91.
[http://dx.doi.org/10.1016/S0021-9150(99)00014-3] [PMID: 10407499]
[76]
Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5(12): 2073-81.
[PMID: 7579056]
[77]
Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009; 94(8): 2692-701.
[http://dx.doi.org/10.1210/jc.2009-0370] [PMID: 19470627]
[78]
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37(39): 2999-3058.
[http://dx.doi.org/10.1093/eurheartj/ehw272] [PMID: 27567407]
[79]
Anagnostis P, Paschou SA, Goulis DG, Athyros VG, Karagiannis A. Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit? Maturitas 2018; 108: 45-52.
[http://dx.doi.org/10.1016/j.maturitas.2017.11.011] [PMID: 29290214]
[80]
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidaemia and prevention of cardiovascular disease. Endocr Pract 2017; 23(Suppl. 2): 1-87.
[http://dx.doi.org/10.4158/EP171764.APPGL] [PMID: 28437620]
[81]
Knoll GA, Blydt-Hansen TD, Campbell P, et al. Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis 2010; 56(2): 219-46.
[http://dx.doi.org/10.1053/j.ajkd.2010.05.004] [PMID: 20659623]
[82]
Gotsis E, Anagnostis P, Mariolis A, Vlachou A, Katsiki N, Karagiannis A. Health benefits of the Mediterranean Diet: an update of research over the last 5 years. Angiology 2015; 66(4): 304-18.
[http://dx.doi.org/10.1177/0003319714532169] [PMID: 24778424]
[83]
Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018; 378(25) e34
[http://dx.doi.org/10.1056/NEJMoa1800389] [PMID: 29897866]
[84]
de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99(6): 779-85.
[http://dx.doi.org/10.1161/01.CIR.99.6.779] [PMID: 9989963]
[85]
Barbagallo CM, Cefalù AB, Gallo S, et al. Effects of Mediterranean diet on lipid levels and cardiovascular risk in renal transplant recipients. Nephron 1999; 82(3): 199-204.
[http://dx.doi.org/10.1159/000045403] [PMID: 10395991]
[86]
Chauveau P, Aparicio M, Bellizzi V, et al. Mediterranean diet as the diet of choice for patients with chronic kidney disease. Nephrol Dial Transplant 2018; 33(5): 725-35.
[http://dx.doi.org/10.1093/ndt/gfx085] [PMID: 29106612]
[87]
Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2014; 1 CD005019
[http://dx.doi.org/10.1002/14651858.CD005019.pub4] [PMID: 24470059]
[88]
Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361(9374): 2024-31.
[http://dx.doi.org/10.1016/S0140-6736(03)13638-0] [PMID: 12814712]
[89]
Robertsen I, Asberg A, Granseth T, et al. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. Transplantation 2014; 97(12): 1266-71.
[http://dx.doi.org/10.1097/01.TP.0000443225.66960.7e] [PMID: 24521776]
[90]
Romero R, Calviño J, Rodriguez J, Sánchez-Guisande D. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins. Nephrol Dial Transplant 2000; 15(9): 1446-9.
[http://dx.doi.org/10.1093/ndt/15.9.1446] [PMID: 10978406]
[91]
Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens 2009; 18(5): 404-11.
[http://dx.doi.org/10.1097/MNH.0b013e32832edcb2] [PMID: 19593130]
[92]
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372(25): 2387-97.
[http://dx.doi.org/10.1056/NEJMoa1410489] [PMID: 26039521]
[93]
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-92.
[http://dx.doi.org/10.1016/S0140-6736(11)60739-3] [PMID: 21663949]
[94]
Savvidaki E, Koukoulaki M, Benou A, et al. Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients. Clin Nephrol 2011; 75(2): 107-12.
[http://dx.doi.org/10.5414/CNP75107] [PMID: 21255539]
[95]
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16): 1489-99.
[http://dx.doi.org/10.1056/NEJMoa1501031] [PMID: 25773378]
[96]
Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16): 1500-9.
[http://dx.doi.org/10.1056/NEJMoa1500858] [PMID: 25773607]
[97]
Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014; 114(5): 711-5.
[http://dx.doi.org/10.1016/j.amjcard.2014.05.060] [PMID: 25060413]
[98]
Zheng-Lin B, Ortiz A. Lipid management in chronic kidney disease: systematic review of PCSK9 targeting. Drugs 2018; 78(2): 215-29.
[http://dx.doi.org/10.1007/s40265-017-0858-2] [PMID: 29299849]
[99]
Lim AK, Manley KJ, Roberts MA, Fraenkel MB. Fish oil for kidney transplant recipients. Cochrane Database Syst Rev 2016; 8 CD005282
[PMID: 27535773]

Rights & Permissions Print Cite
Article Metrics
20
4
© 2024 Bentham Science Publishers | Privacy Policy